BioCentury
ARTICLE | Emerging Company Profile

858: Versant’s second start-up targeting RNA-modifying proteins

Emerging Company Profile: Building on a predecessor epitranscriptomics company, 858 brings together VCs and familiar team

September 21, 2021 12:01 PM GMT
Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article